North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297
Recruiting
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/14/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Neutropenia
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: Research Site, Asheville, North Carolina
Conditions: Asthma
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
04/14/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Atrial Fibrillation
Register for Updates
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
NCT05785624
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/14/2025
Locations: Pulmonix LLC, Greensboro, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Register for Updates
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645
Recruiting
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survi... Read More
Gender:
ALL
Ages:
Between 6 years and 39 years
Trial Updated:
04/14/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Down Syndrome, B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
NCT05692635
Recruiting
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Register for Updates
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/14/2025
Locations: Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Aortic Stenosis
Register for Updates
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028
Recruiting
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Levine Cancer Institute /ID# 246363, Charlotte, North Carolina
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Register for Updates
Virtual Reality Mindfulness Meditation After ACL Reconstruction
NCT05527171
Recruiting
To evaluate the effect of virtual reality mindfulness meditation on patients after ACLR, the investigators will determine the effect of virtual reality mindfulness meditation to 1) decrease self-reported injury-related fear, 2) improve poor jump-landing movement patterns, and 3) improve brain activity in women 1 to 5 years post-ACLR when compared to a virtual reality sham group.
Gender:
FEMALE
Ages:
Between 14 years and 25 years
Trial Updated:
04/14/2025
Locations: Fetzer Hall, 210 South Road, Chapel Hill, North Carolina
Conditions: Anterior Cruciate Ligament Injury
Register for Updates
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
NCT05451004
Recruiting
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Oropharyngeal Cancer
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: Duke University, Durham, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05346354
Recruiting
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: Research Site, Durham, North Carolina
Conditions: Neuromyelitis Optica Spectrum Disorder
Register for Updates